(P082) Outcomes of Definitive Radiotherapy for T2N0 Squamous Cell Carcinoma of the Glottis: A Single-Institution Retrospective Study

Publication
Article
OncologyOncology Vol 29 No 4_Suppl_1
Volume 29
Issue 4_Suppl_1

Excellent 5-year oncologic and functional outcomes were achieved for patients presented in the study. The use of altered fractionation, concurrent chemotherapy, and different radiation techniques did not show any significant differences in outcomes. However, the reduced radiation dose delivered to the carotid arteries using IMRT suggests that it is potentially advantageous for reduction of long-term vascular toxicity and is therefore recommended as the treatment of choice.

Bassem Y. Youssef, MD, Abdallah S. Mohamed, MD, MSc, Blaine D. Smith, G. Brandon Gunn, MD, Jack Phan, MD, PhD, William H. Morrison, MD, Adam S. Garden, MD, David I. Rosenthal, MD, Clifton D. Fuller, MD, PhD; UT MD Anderson Cancer Center

BACKGROUND: The aim of this study is to report the oncologic and functional outcomes of patients with T2N0M0 squamous cell carcinoma (SCC) of the glottis treated with radiation therapy (RT).

METHODS: Sequential patients treated with definitive RT for T2 glottic SCC at our facility between 2000 and 2013 were retrospectively reviewed under an approved institutional review board (IRB) protocol. Demographics, disease stage, and treatment characteristics were extracted. Local control and survival outcomes at 2 and 5 years of follow-up were calculated. Both univariate analysis and multivariate Cox proportional hazards assessment were performed to investigate the correlation of patient- and treatment-related factors with disease control and survival endpoints.

RESULTS: A total of 68 patients were included in the analysis. The median follow-up was 55 months (range: 5–173 mo); 58 (85%) of the patients were male, and the median age was 63 years (range: 18–88 yr). Of the 68 patients, 20 (29%) were treated using intensity-modulated radiotherapy (IMRT), and the remainder was treated using conventional three-dimensional conformal radiotherapy (3DCRT). Further, 18 patients (26%) were treated using altered fractions schemes, while the rest were treated conventionally. The local control (LC) and locoregional control (LRC) rates at 2 and 5 years were 89% and 84%, and 87% and 82%, respectively. The rate of ultimate LRC was 100%, with no single second recurrence after successful surgical salvage. The disease-specific survival (DSS) was 95% at both 2 and 5 years, with a corresponding OS of 92% and 88%, respectively. In both univariate and multivariate analyses, none of the examined variables (age, pathologic grade, radiation technique, fractionation scheme, total dose, and chemotherapy) was associated with local recurrence or mortality, except for older age, which was associated with worse OS only in the univariate analysis (P < .0001).Regarding functional outcome, only one patient was feeding tube–dependent at the 1 year follow-up due to persistence of grade 3 dysphagia; 60% of patients had no hoarseness of voice at the last follow-up assessment.

CONCLUSIONS: Excellent 5-year oncologic and functional outcomes were achieved for patients presented in the study. The use of altered fractionation, concurrent chemotherapy, and different radiation techniques did not show any significant differences in outcomes. However, the reduced radiation dose delivered to the carotid arteries using IMRT suggests that it is potentially advantageous for reduction of long-term vascular toxicity and is therefore recommended as the treatment of choice. 

Proceedings of the 97th Annual Meeting of the American Radium Society- americanradiumsociety.org

Articles in this issue

(P005) Ultrasensitive PSA Identifies Patients With Organ-Confined Prostate Cancer Requiring Postop Radiotherapy
(P001) Disparities in the Local Management of Breast Cancer in the United States According to Health Insurance Status
(P002) Predictors of CNS Disease in Metastatic Melanoma: Desmoplastic Subtype Associated With Higher Risk
(P003) Identification of Somatic Mutations Using Fine Needle Aspiration: Correlation With Clinical Outcomes in Patients With Locally Advanced Pancreatic Cancer
(P004) A Retrospective Study to Assess Disparities in the Utilization of Intensity-Modulated Radiotherapy (IMRT) and Proton Therapy (PT) in the Treatment of Prostate Cancer (PCa)
(S001) Tumor Control and Toxicity Outcomes for Head and Neck Cancer Patients Re-Treated With Intensity-Modulated Radiation Therapy (IMRT)-A Fifteen-Year Experience
(S003) Weekly IGRT Volumetric Response Analysis as a Predictive Tool for Locoregional Control in Head and Neck Cancer Radiotherapy 
(S004) Combination of Radiotherapy and Cetuximab for Aggressive, High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: A Propensity Score Analysis
(S005) Radiotherapy for Carcinoma of the Hypopharynx Over Five Decades: Experience at a Single Institution
(S002) Prognostic Value of Intraradiation Treatment FDG-PET Parameters in Locally Advanced Oropharyngeal Cancer
(P006) The Role of Sequential Imaging in Cervical Cancer Management
(P008) Pretreatment FDG Uptake of Nontarget Lung Tissue Correlates With Symptomatic Pneumonitis Following Stereotactic Ablative Radiotherapy (SABR)
(P009) Monte Carlo Dosimetry Evaluation of Lung Stereotactic Body Radiosurgery
(P010) Stereotactic Body Radiotherapy for Treatment of Adrenal Gland Metastasis: Toxicity, Outcomes, and Patterns of Failure
(P011) Stereotactic Radiosurgery and BRAF Inhibitor Therapy for Melanoma Brain Metastases Is Associated With Increased Risk for Radiation Necrosis
Related Videos
Collaboration among nurses, social workers, and others may help in safely administering outpatient bispecific T-cell engager therapy to patients.
Nurses should be educated on cranial nerve impairment that may affect those with multiple myeloma who receive cilta-cel, says Leslie Bennett, MSN, RN.
Treatment with cilta-cel may give patients with multiple myeloma “more time,” according to Ishmael Applewhite, BSN, RN-BC, OCN.
Nurses may need to help patients with multiple myeloma adjust to walking differently in the event of peripheral neuropathy following cilta-cel.
Tailoring neoadjuvant therapy regimens for patients with mismatch repair deficient gastroesophageal cancer represents a future step in terms of research.
Not much is currently known about the factors that may predict pathologic responses to neoadjuvant immunotherapy in this population, says Adrienne Bruce Shannon, MD.
Data highlight that patients who are in Black and poor majority areas are less likely to receive liver ablation or colorectal liver metastasis in surgical cancer care.
Findings highlight how systemic issues may impact disparities in outcomes following surgery for patients with cancer, according to Muhammad Talha Waheed, MD.
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Adrienne Bruce Shannon, MD, discussed ways to improve treatment and surgical outcomes for patients with dMMR gastroesophageal cancer.
Related Content